Alternative source of stem cells derived from human periodontal ligament: a new treatment for experimental autoimmune encephalomyelitis by Diomede, Francesca et al.
IJAE 
Vo l .  121,  n .  1  (Supp lem ent) :  159,  2016
© 2016 Firenze University Press 
ht tp://www.fupress .com/ijae
ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY
Alternative source of stem cells derived from 
human periodontal ligament: a new treatment for 
experimental autoimmune encephalomyelitis 
Francesca Diomede 1 - Sabrina Giacoppo 2 - Ilaria Merciaro 1 - Patrizia Ballerini 3 - Placido 
Bramanti 2 - Emanuela Mazzon 2 - Oriana Trubiani 1
1 Università degli Studi “G. d’Annunzio”, Chieti-Pescara, Dipartimento di Scienze Mediche, Orali e 
Biotecnologiche, Chieti, Italia -2 IRCCS Centro Neurolesi “Bonino Pulejo”, Laboratorio di Neurologia 
Sperimentale, Messina, Italia - 3 Università degli Studi “G. d’Annunzio”, Chieti-Pescara, Dipartimento di Scienze 
Psicologiche, della Salute e del Territorio, Chieti, Italia 
Multiple sclerosis (MS) is categorized as an autoimmune disease and is potentially one of 
the most common causes of neurological disability in young adults. Formation of the sclerot-
ic plaques of which the disease gets its name represents the end stage of a process involving 
inflammation, demyelination and remyelination, oligodendrocytes depletion, and astrogliosis 
as well as neuronal and axonal degeneration (1). MS damages the central nervous system and 
leads to a disabling condition. Recently, the potential role of mesenchymal stem cells (MSCs), 
derived in promoting tissue repair and disease control has been investigated by using an exper-
imental autoimmune encephalomyelitis (EAE) model (2). The objective of the research was to 
investigate the product effects by mesenchymal stem cells derived from human periodontal 
ligament (hPDLSCs) when administered in an experimental model of autoimmune encephalo-
myelitis (EAE). EAE was induced by immunization with myelin oligodendroglial glycoprotein 
peptide (MOG)35-55 in C57BL/6 mice. Then, mice were observed every 48 hours for signs of 
EAE and weight loss. At the onset of disease, approximately 14 days after immunization, EAE 
mice were subjected to a single intravenous injection of hPDLSCs (10(6) cells/150 μl) into the 
tail vein. At the point of animal sacrifice on day 56 after EAE induction, spinal cord and brain 
tissues were collected in order to perform histological evaluation, immunohistochemistry and 
western blotting analysis. Obtained results reveal that treatment with hPDLSCs may produce 
neuroprotective effects against EAE, diminishing both clinical signs and histological score typi-
cal of the disease (lymphocytic infiltration and demyelination) probably through the production 
of neurotrophic factors (results focused on brain-derived neurotrophic factor and nerve growth 
factor expression). Furthermore, administration of hPDLSCs modulates expression of inflam-
matory key markers (tumor necrosis factor-α, interleukin (IL)-1β, IL-10, glial fibrillary acidic 
protein, Nrf2 and Foxp3), the release of CD4 and CD8α T cells, and the triggering of apop-
totic death pathway (data shown for cleaved caspase 3, p53 and p21). In light of the achieved 
results, transplantation of hPDLSCs may represent a putative novel and helpful tool for multi-
ple sclerosis treatment. These cells could have considerable implication for future therapies for 
multiple sclerosis and this study may represent the starting point for further investigations.
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